PIK3CB
ENSG00000051382
Target class
Enzyme
Chromosome
3
Approved drugs
0
Clinical candidates (approved and in development)
31
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 31
- Chemical probe available
- Yes
- Target name
- PIK3CB
- Gene name
- Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
- Gene symbol
- PIK3CB
- Previous gene symbols
- PIK3C1
- Protein name
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PI3-kinase subunit beta) (PI3K-beta) (PI3Kbeta) (PtdIns-3-kinase subunit beta) (EC 2.7.1.153) (Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit beta) (PtdIns-3-kinase subunit p110-beta) (p110beta) (Serine/threonine protein kinase PIK3CB) (EC 2.7.11.1)
- Gene biotype
- Protein coding
- Gene family
- Phosphatidylinositol 3-kinase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 28.01
- Tissue specificity (Gini)
- 0.195
- Tissue specificity (tau)
- 0.623
- KEGG gene identifiers
- hsa:5291
- Protein interaction confidence
- 0.892834
- Protein interaction partners
- 151
- R-HSA-109704
- R-HSA-112399
- R-HSA-114604
- R-HSA-1257604
- R-HSA-1660499
- R-HSA-186763
- R-HSA-198203
- R-HSA-201556
- R-HSA-202424
- R-HSA-2029485
- R-HSA-210993
- R-HSA-2219530
- R-HSA-2424491
- R-HSA-2730905
- R-HSA-373753
- R-HSA-389357
- R-HSA-4420097
- R-HSA-512988
- R-HSA-5673001
- R-HSA-6811558
- R-HSA-8853659
- R-HSA-9027276
- R-HSA-912526
- R-HSA-912631
- R-HSA-9673767
And 7 more, listed on the interactive page.
- End position
- 138834957
- Start position
- 138652336
- Chromosome
- 3
- Strand
- Reverse
- Cytoplasm . Nucleus . Note=Interaction with PIK3R2 is required for nuclear localization and export.
- Midbody
- Nucleoli
- Nucleoplasm
- Vesicles
Publication evidence
- PubMed 21383062
- Tissue specificity (tau)
- 0.62279
- Expression inequality (Gini)
- 0.19475
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 28.01
- Thyroid
- 22.15
- Brain - Cerebellum
- 21.84
- Skin - Sun Exposed (Lower leg)
- 20.33
- Skin - Not Sun Exposed (Suprapubic)
- 19.87
Expression in transcripts per million
- Brain - Cerebellar Hemisphere28.01
- Thyroid22.15
- Brain - Cerebellum21.84
- Skin - Sun Exposed (Lower leg)20.33
- Skin - Not Sun Exposed (Suprapubic)19.87
- Brain - Frontal Cortex (BA9)18.19
- Brain - Cortex13.12
- Artery - Tibial12.63
- Vagina12.41
- Esophagus - Mucosa12.3
- Muscle - Skeletal11.98
- Esophagus - Muscularis11.87
- Adipose - Subcutaneous11.82
- Prostate11.63
- Breast - Mammary Tissue11.27
- Minor Salivary Gland11.27
- Artery - Aorta11
- Bladder10.97
- Fallopian Tube10.95
- Nerve - Tibial10.9
- Esophagus - Gastroesophageal Junction10.9
- Lung10.72
- Cells - Cultured fibroblasts10.46
- Cervix - Ectocervix10.43
- Cells - EBV-transformed lymphocytes10.34
And 29 more, listed on the interactive page.
- GO:0001952
- GO:0003376
- GO:0006935
- GO:0007169
- GO:0007186
- GO:0010508
- GO:0010595
- GO:0010628
- GO:0016477
- GO:0030168
- GO:0033031
- GO:0035022
- GO:0042267
- GO:0043491
- GO:0045429
- GO:0046854
- GO:0051898
- GO:0070527
- GO:1900747
- GO:1903671
- GO:2000369
- GO:0005634
- GO:0005654
- GO:0005730
- GO:0005737
- GO:0005829
- GO:0005515
- GO:0016303
- GO:0046934
- GO:0106310
Related records
Trials (214)
- 5G-PEARL: Paxalisib in Malignant Brain Tumours
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
- A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
- A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
- A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
- A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
- A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
- A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
- A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
- A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
- A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
- A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
Drugs (33)
- Apitolisib PI3-kinase class I inhibitor
- AZD-6482 PI3-kinase class I inhibitor
- AZD-8186 PI3-kinase p110-beta subunit inhibitor
- BAY-1082439 PI3-kinase p110-beta subunit inhibitor
- BGT-226 PI3-kinase class I inhibitor
- BGT-226 FREE BASE PI3-kinase class I inhibitor
- Buparlisib PI3-kinase class I inhibitor
- Dactolisib PI3-kinase class I inhibitor
- DS-7423 PI3-kinase class I inhibitor
- Fimepinostat PI3-kinase p110-beta subunit inhibitor
- Gedatolisib PI3-kinase class I inhibitor
- GSK-1059615 PI3-kinase class I inhibitor
- GSK-2636771 PI3-kinase p110-beta subunit inhibitor
- Izorlisib PI3-kinase class I inhibitor
- Omipalisib PI3-kinase class I inhibitor
- Panulisib PI3-kinase class I inhibitor
- Paxalisib PI3-kinase class I inhibitor
- PF-04691502 PI3-kinase class I inhibitor
- Pictilisib PI3-kinase class I inhibitor
- Pilaralisib PI3-kinase class I inhibitor